1. Why This Question Is Being Asked Now

In November 2018 cannabis-based products for medicinal use were rescheduled from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001, making them prescribable in the UK by doctors on the General Medical Council Specialist Register. The expectation at the time was that access would develop through the NHS. It did not. NHS prescribing has remained confined to a small number of licensed or exceptional cases — principally rare severe epilepsy, chemotherapy-induced nausea and vomiting, and spasticity in multiple sclerosis — and the entire practical market has developed privately.

The scale of that private market is now material. Prohibition Partners' 2026 UK market update estimates a market of £302–389 million serving more than 140,000 patients, against roughly 30,000 kg of CBPM imported in 2025 and over 800 products available by March 2026. Growth of that shape, in a sector with modest capital requirements and no premises requirement for a remote-first model, inevitably attracts clinicians from adjacent private specialties — aesthetic medicine among them.

What has not developed at the same pace is a sober, numbers-first account of what entering the sector involves. The available material is either regulatory guidance written for compliance officers or founder-interview content written for investors. This review is intended for the third audience: the clinician who wants to know what it costs, where the revenue actually comes from, and whether the risk-adjusted return justifies the governance burden.

2. The Regulatory Perimeter: What You Must Have Before You Trade

Four separate regulatory questions determine whether a proposed service is lawful. They are frequently conflated, and conflating them is the most common early error.

CQC registration. Providing a regulated activity in England requires registration with the Care Quality Commission, in this case for the regulated activity of treatment of disease, disorder or injury. If an existing registered service begins offering CBPMs, or begins prescribing them remotely, it must update its statement of purpose and notify CQC in writing within 28 days. Some individual independent doctors are exempt from registration; most corporate structures are not, and structuring the service specifically to fall within an exemption is a decision that should be taken with regulatory advice rather than optimism. Equivalent registration applies in Scotland (Healthcare Improvement Scotland), Wales (Healthcare Inspectorate Wales) and Northern Ireland (RQIA).

Prescriber status. CBPMs are unlicensed medicines. They may only be initiated by a doctor on the GMC Specialist Register — not by a GP on the GP Register acting alone, not by a non-medical prescriber, and not by an aesthetic practitioner on the basis of any aesthetics qualification. GMC guidance additionally states that unlicensed medicines should not be used as first-line treatment where a licensed alternative could meet the patient's need. This single requirement is the sector's real barrier to entry: the scarce resource is not capital, it is specialist-registered prescribing time in the relevant clinical specialism.

Multidisciplinary governance. CQC expects services to be able to demonstrate a process that scrutinises and ratifies each decision to initiate a CBPM, with a minimum of two GMC specialist-registered doctors participating in the multidisciplinary team, in person or asynchronously, and with the prescribing specialist holding specialism relevant to the condition being treated. In practice this means an MDT that meets on a defined cycle, keeps minutes, and can evidence that unmet clinical need was established before initiation. It is a recurring cost, not a one-off document.

Controlled drug handling. Schedule 2 status brings safe custody, record-keeping, destruction and accountable-officer obligations wherever the product is physically held. A clinic that prescribes and routes dispensing to a licensed specialist pharmacy does not require a Home Office domestic licence; a business that intends to possess, supply, produce or cultivate does, and the published application fees are £3,133 (possess), £3,655 (supply), £4,178 (produce preparations) and £4,700 (produce or cultivate), with renewal at £326 where no compliance visit is required and £1,371 where one is. For the overwhelming majority of new clinics the correct answer is to prescribe and not to touch stock.

3. What It Actually Costs to Set Up

Regulatory fees are the least significant line in the budget, which surprises most people. Under the current CQC fees scheme a single-location healthcare single-speciality service pays £1,743 annually; a single-location community healthcare service pays £1,867. Those are annual regulatory fees, not the cost of becoming registerable.

The cost of becoming registerable sits in clinical governance construction: a statement of purpose, a full policy suite covering prescribing, safeguarding, controlled drugs, remote consultation, information governance and complaints, a registered manager, a nominated individual, DBS checks, and an evidenced MDT process. Bought in as consultancy this is commonly £8,000–25,000; built internally it is three to six months of senior clinical time, which is the same cost expressed differently.

Software is the second structural cost. A compliant remote clinic needs a clinical record system, e-prescribing capable of handling Schedule 2 private prescriptions, identity verification, secure video consultation, payment and subscription billing, and a patient portal. Configured platforms typically run £1,000–4,000 per month at small scale; bespoke build is a six-figure decision that no first-year clinic should make.

Insurance and indemnity is the third. Prescribing unlicensed Schedule 2 medicines remotely is not a standard risk, and indemnity must be arranged specifically on that basis. Assume a meaningful premium uplift over routine private practice and confirm the wording before the first consultation, not after.

Patient acquisition is the largest line by some distance and the one most often omitted from projections. Cannabis advertising restrictions, prescription-only medicine advertising rules and mainstream platform policies severely limit paid channels, which pushes acquisition into organic search, comparison sites, patient communities and affiliate arrangements. Content and SEO-led acquisition is slow, front-loaded and cumulative — a twelve-to-eighteen-month investment before it carries the list.

A defensible first-year model for a small, remote-first, two-specialist clinic therefore lands at approximately £70,000 at the disciplined end and £160,000 at the realistic end, excluding founder drawings, and split roughly: governance and consultancy 15%, software and infrastructure 20%, clinical time and MDT 25%, insurance and professional fees 10%, marketing and acquisition 30%. Premises, if taken, add materially and buy very little in a model where consultations are remote.

4. Where the Revenue Actually Comes From

The single most important commercial fact about this sector is that consultation revenue has been competed almost to zero. Publicly advertised pricing at the time of writing includes £30 per appointment with a typical first-year appointment cost of £120, monthly subscriptions from £5, annual plans from £50, and introductory consultation offers as low as £9.99 against a £99.99 list price. A clinician entering the market with a £250 initial consultation and £150 follow-ups will not acquire patients, regardless of the quality of the assessment.

Revenue is therefore made on the medicine and on retention, not on the appointment. Indicative patient-facing medicine pricing published by an established clinic gives dried flower from approximately £5.50 per gram, THC oils from £30 per 10 ml, CBD and combination oils from £50 per 10 ml, pastilles at £22–34 for fourteen and vape cartridges at £30–55. A patient prescribed 30 g per month at the lower end is spending in the region of £165 monthly on medicine alone; heavier or oil-plus-flower regimens commonly reach £300–400.

That gives three viable revenue architectures. The first is the pure prescribing clinic, which earns only the subscription and any repeat-prescription administration fee, and is economically marginal unless the list is large. The second is the vertically integrated model, in which the group also owns or has commercial arrangements with the dispensing pharmacy or import route and captures product margin — this is where the sector's actual profit sits, and it requires capital, licensing and scale. The third is the specialist niche clinic, serving a defined condition group (for example chronic pain, PTSD, or paediatric-adjacent neurology under appropriate specialism) at higher clinical intensity, modest volume and a defensible fee, competing on outcome and MDT quality rather than on price.

Retention dominates all three. A CBPM patient on stable therapy is a multi-year relationship with recurring prescription cycles; a patient lost at month three has consumed the entire acquisition cost and returned a subscription payment. The metric that decides whether the business works is not consultations booked but the ratio of lifetime medicine value to cost of acquisition, and any projection that does not model twelve-month retention explicitly is decorative.

5. A Worked Unit-Economics Model

Take a small clinic charging a £50 annual plan covering an initial assessment and four routine reviews, dispensing through a partner pharmacy at an agreed margin, and acquiring patients at a blended cost of £120 through organic and affiliate channels.

On the pure-prescribing architecture, annual revenue per retained patient is £50 plus repeat administration, against a delivery cost dominated by clinician time: an initial assessment plus MDT ratification plus four reviews is realistically 90–120 minutes of clinical and administrative time per patient per year. At any defensible internal cost of clinical time, that patient is loss-making on subscription alone. The model only closes if a share of medicine value returns to the group.

On the integrated architecture, a patient spending £200 monthly on medicine generates £2,400 of annual product turnover. A 20–30% blended margin returns £480–720 per patient per year against a £120 acquisition cost and perhaps £150–200 of delivery cost — a contribution of roughly £150–400 per patient per year. A thousand retained patients therefore produce £150,000–400,000 of annual contribution before central overhead, which is a real business but requires roughly £120,000 of acquisition spend to build and eighteen to twenty-four months to reach.

On the specialist niche architecture, a clinic charging £250 for a genuinely comprehensive initial assessment and £120 for reviews, serving 300 patients at higher clinical intensity, generates approximately £200,000 of consultation revenue with far lower acquisition volume, but is exposed to price comparison against £9.99 competitors and must be able to articulate clearly what the additional fee buys.

Two sensitivities break every version of this model. The first is retention: a fall from 70% to 50% twelve-month retention removes roughly a third of lifetime value while leaving acquisition cost unchanged. The second is specialist prescribing capacity, which is the binding constraint on growth — a clinic cannot scale past the hours its specialist-registered prescribers and second MDT doctors can provide, and those hours are expensive, scarce and not substitutable.

6. Advantages: The Honest Case For

Recurring, non-discretionary revenue. Unlike aesthetic treatment, a CBPM prescription is therapeutic and continues through economic downturns. Revenue is subscription-shaped and forecastable, which is unusual in private practice and valuable to lenders and acquirers.

Structural undersupply. Fewer than one in a thousand of the estimated UK patient population who might benefit is currently treated on the NHS, and awareness continues to rise. Demand is not the constraint.

Low capital intensity. A remote-first clinic requires no treatment rooms, no capital equipment and no stock. The dominant costs are people and marketing, both of which can be scaled up and down.

Regulatory moat. The Specialist Register requirement, MDT ratification and CQC registration together deter casual entrants. Once built, a compliant governance structure is a genuine competitive asset rather than pure cost.

Clinical depth. For clinicians in pain medicine, neurology, psychiatry, palliative care or rheumatology, this is real medicine with an evolving evidence base, patient-reported outcome registries and a legitimate research contribution — a considerably more substantial professional proposition than most private ventures.

Transferable infrastructure. The governance, remote-consultation and subscription-billing infrastructure built for a CBPM service is directly reusable for other regulated remote services, which improves the strategic value of the build.

7. Disadvantages: The Honest Case Against

Price competition has already happened. Entry-level consultation pricing at £5 per month or £9.99 per consultation was set by venture-funded operators buying market share. A new entrant is competing against pricing that was never intended to be profitable in isolation, and cannot win that fight on price.

The margin lives with the pharmacy and the importer. A clinic that only prescribes occupies the least profitable position in the value chain while carrying most of the clinical risk. Any business plan that does not address this explicitly is planning to work hard for someone else's margin.

Prescriber dependency. The business is structurally hostage to a small number of specialist-registered doctors. Losing one can halt initiations entirely, and there is no rapid replacement market.

Regulatory fragility. A single governance failure — inadequate MDT scrutiny, first-line use of an unlicensed product, weak identity verification, poor record-keeping around Schedule 2 prescriptions — is not a fine, it is a potential registration and licensing event with GMC consequences for the individuals involved.

Marketing constraint. Prescription-only medicine advertising rules and platform policies close most performance-marketing channels, which pushes acquisition toward slow organic routes with long payback periods. Clinicians accustomed to paid social acquisition in aesthetics will find the channel mix unrecognisable.

Reputational adjacency. Fair or not, an aesthetics brand that adds cannabis prescribing invites patients, peers and regulators to ask which one is the business. If the two are offered under the same brand, the clinical separation must be visible, documented and defensible.

Policy risk in both directions. Wider NHS access would remove the private market's reason to exist; regulatory tightening would raise costs. A model that only works within a narrow band of the current policy settlement is a fragile model.

8. Guidance for Clinicians Considering Entry

Establish prescriber access before anything else. Do not register a company, buy a domain or commission branding until at least two GMC specialist-registered doctors with relevant specialism have committed contractually to prescribing and MDT participation. Everything downstream is contingent on that and nothing upstream substitutes for it.

Decide your position in the value chain deliberately. Prescribing-only, integrated with dispensing, or specialist niche. Each has a different capital requirement, a different regulatory footprint and a different profit pool. Drifting into prescribing-only by default is the standard failure mode.

Model retention before revenue. Build the twelve-month retention assumption first, then acquisition cost, then lifetime value. If lifetime value does not exceed three times acquisition cost, the model does not work at any volume.

Fund eighteen months of acquisition. Organic acquisition in a restricted-advertising sector compounds slowly. Clinics fail at month nine with a working model and no runway far more often than they fail with a broken model.

Build governance as product, not as paperwork. MDT quality, documentation and outcome tracking are the only durable differentiators available in a market where price has already bottomed. They are also what protects the registration.

Keep it structurally separate from aesthetic practice. Separate registration where required, separate brand, separate consent architecture, separate record-keeping. Contamination between an elective cosmetic offer and an unlicensed Schedule 2 therapeutic offer is a governance risk with no commercial upside.

Contribute to the evidence base. Participation in patient registries and outcome reporting strengthens the clinical case, supports the MDT record and provides the material for legitimate professional visibility in a sector where conventional advertising is closed.

9. The Wider Lesson for Private Aesthetic Practice

The specific opportunity here will suit a minority of readers. The method should suit all of them. What distinguishes clinicians who successfully add a regulated service line from those who lose money doing it is not clinical ability but the willingness to complete four steps before committing capital: identify the binding regulatory constraint, locate the profit pool in the value chain, model retention and acquisition cost honestly, and separate the new service from the existing one structurally.

Applied to medical cannabis, those four steps produce a clear answer — a viable, demanding, governance-heavy subscription business for clinicians with specialist prescribing access and eighteen months of patience, and a reliable way to lose £100,000 for everyone else.

Applied to the next opportunity that appears in the trade press — and one will — they produce an answer faster and more cheaply than the alternative, which is finding out.

10. Conclusion

Opening a medical cannabis clinic in the UK is legally straightforward and commercially difficult, which is the opposite of how it is usually presented. The regulatory fees are small; the governance obligation is permanent. The demand is real; the consultation price has already been competed to nothing. The market is growing; the margin sits with the pharmacy and the importer rather than the prescriber.

For clinicians who can secure specialist-registered prescribing capacity, take a defensible position in the value chain, and fund a long organic acquisition curve, it is a genuine business with recurring revenue and a real clinical contribution. For clinicians looking to add a revenue line to an existing aesthetic list, it is a regulated distraction with an unfavourable risk profile.

The decision should be made on the arithmetic in sections three to five, not on the market-size headline. That is the whole argument.